‘‘(B) DETERMINATION.—If the Director of 
the Office of Government Ethics determines 
that participation by a member of the Board in 
high-risk life sciences research constitutes a 
conflict of interest, the Board shall take steps 
to mitigate or manage the conflict, which may 
include— 
‘‘(i) the recusal of the affected mem-
ber from relevant discussions and deter-
minations; and 
‘‘(ii) removal of the affected member 
from the Board. 
‘‘(f) COMPENSATION OF MEMBERS.— 
‘‘(1) IN GENERAL.—Subject to such rules as 
may be adopted by the Board, without regard to the 
provisions of chapter 51 and subchapter III of chap-
ter 53 of title 5 relating to classification and Gen-
eral Schedule pay rates, a member of the Board, 
other than the Executive Director, shall be com-
pensated at a rate— 
‘‘(A) proposed by the Executive Director 
and approved by the Board; 
‘‘(B) not to exceed the rate of basic pay 
for level II of the Executive Schedule; and 
‘‘(C) that is commensurate with— 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(i) the time a member of the Board 
spends engaged in the performance of du-
ties on the Board; and 
‘‘(ii) necessary traveling expenses. 
‘‘(2) OUTSIDE EMPLOYMENT.—Subject to terms 
and approval determined by the Director of the Of-
fice of Government Ethics, a member of the Board 
may maintain outside employment and affiliations 
while serving on the Board. 
‘‘(g) OVERSIGHT.— 
‘‘(1) SENATE.—The Committee on Homeland 
Security and Governmental Affairs of the Senate 
shall— 
‘‘(A) have continuing legislative oversight 
jurisdiction in the Senate with respect to the of-
ficial conduct of the Board and agency compli-
ance with requirements issued by the Board; 
and 
‘‘(B) have access to any records provided 
to or created by the Board. 
‘‘(2) HOUSE OF REPRESENTATIVES.—The Com-
mittee on Energy and Commerce of the House of 
Representatives shall— 
‘‘(A) have continuing legislative oversight 
jurisdiction in the House of Representatives 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
with respect to the official conduct of the Board 
and agency compliance with requirements 
issued by the Board; and 
‘‘(B) have access to any records provided 
to or created by the Board. 
‘‘(3) DUTY TO COOPERATE.—The Board shall 
have the duty to cooperate with the exercise of over-
sight jurisdiction described in this subsection. 
‘‘(4) SECURITY CLEARANCES.—The chair and 
ranking member of the appropriate congressional 
committees, and designated committee staff, shall be 
granted all security clearances and accesses held by 
the Board, including to relevant Presidential and de-
partment or agency special access and compart-
mented access programs. 
‘‘(h) OFFICE SPACE.— 
‘‘(1) IN GENERAL.—In selecting office space for 
the Board, the Board shall exhaust options for un-
used office spaces owned by the Federal Government 
as of the date of enactment of this chapter. 
‘‘(2) SECURE OFFICE SPACE.— 
‘‘(A) REQUESTS.—In order to review or 
discuss classified information, the Board shall 
request an accommodation from relevant agen-
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
cies to access sensitive compartmented informa-
tion facilities on an as-needed basis. 
‘‘(B) FULFILMENT.—The head of an agen-
cy from which the Board requests an accommo-
dation under subparagraph (A) shall accommo-
date the request in a timely manner. 
‘‘§ 7903. Board personnel 
‘‘(a) EXECUTIVE DIRECTOR.— 
‘‘(1) APPOINTMENT.—Not later than 45 days 
after the date of enactment of this chapter, the 
President shall appoint, by and with the advice and 
consent of the Senate, 1 individual who is a citizen 
of the United States, without regard to political af-
filiation, to the position of Executive Director of the 
Board for a term of 4 years. 
‘‘(2) QUALIFICATIONS.—The individual ap-
pointed as Executive Director under paragraph (1) 
shall be a private individual of integrity and impar-
tiality who— 
‘‘(A) is a distinguished scientist in a life 
sciences field; and 
‘‘(B) is not, and has not been for the 3- 
year period preceding the date of the appoint-
ment— 
‘‘(i) an employee; or 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(ii) a participant in high-risk life 
sciences research supported by Federal 
funding. 
‘‘(3) SECURITY CLEARANCES.— 
‘‘(A) IN GENERAL.—A candidate for Exec-
utive Director of the Board shall be granted all 
security clearances and accesses held by the 
Board, including to relevant Presidential and 
department or agency special access and com-
partmented access programs in an accelerated 
manner, subject to the standard procedures for 
granting such clearances. 
‘‘(B) QUALIFICATION PRIOR TO APPOINT-
MENT.—The President shall ensure that a can-
didate for Executive Director of the Board 
qualifies for the security clearances and ac-
cesses described in subparagraph (A) prior to 
appointment. 
‘‘(4) FUNCTIONS.—The Executive Director of 
the Board shall— 
‘‘(A) serve as principal liaison to Congress 
and agencies; 
‘‘(B) serve as chair of the Board; 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(C) be responsible for the administration 
and coordination of the responsibilities of the 
Board; and 
‘‘(D) be responsible for the administration 
of all official activities conducted by the Board. 
‘‘(5) 
REMOVAL.—Notwithstanding 
section 
7902(b)(8), the Executive Director shall not be re-
moved for reasons other than for cause on the 
grounds of inefficiency, neglect of duty, malfeasance 
in office, physical disability, mental incapacity, or 
any other condition that substantially impairs the 
performance of the responsibilities of the Executive 
Director or the staff of the Board. 
‘‘(6) TERMS.—An Executive Director of the 
Board shall not serve more than 2 terms. 
‘‘(b) STAFF.— 
‘‘(1) IN GENERAL.—Without regard to the pro-
visions of subchapter I of chapter 33 of title 5 gov-
erning appointments in the competitive service, the 
Board may appoint not more than 25 additional per-
sonnel to enable the Board and the Executive Direc-
tor to perform the duties of the Board. 
‘‘(2) QUALIFICATIONS.—Each individual ap-
pointed to the staff of the Board— 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(A) shall be a citizen of the United States 
of integrity and impartiality; 
‘‘(B) shall have expertise in the life 
sciences field or the national security field; and 
‘‘(C) may not be a participant in any fed-
erally funded research activity on the date of 
the appointment or during the course of service 
of the individual on the Board. 
‘‘(3) SECURITY CLEARANCES.— 
‘‘(A) IN GENERAL.—A candidate for ap-
pointment to the staff of the Board shall be 
granted all security clearances and accesses 
held by the Board, including to relevant Presi-
dential and department or agency special access 
and compartmented access programs, in an ac-
celerated manner, subject to the standard pro-
cedures for granting such clearances. 
‘‘(B) CONDITIONAL EMPLOYMENT.— 
‘‘(i) IN
GENERAL.—The Board may 
offer conditional employment to a can-
didate for a staff position of the Board 
pending the completion of security clear-
ance background investigations. During 
the pendency of such investigations, the 
Board shall ensure that any such employee 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
does not have access to, or responsibility 
involving, classified or otherwise restricted 
materials. 
‘‘(ii) UNQUALIFIED
STAFF.—If the 
Board determines that an individual hired 
on a conditional basis under clause (i) is 
not eligible or otherwise does not qualify 
for all security clearances necessary to 
carry out the responsibilities of the posi-
tion for which conditional employment has 
been offered, the Board shall immediately 
terminate the individual’s employment. 
‘‘(4) SUPPORT FROM AGENCIES.— 
‘‘(A) IN
GENERAL.—The head of each 
agency shall designate not less than 1 full-time 
employee of the agency as the representative of 
the agency to— 
‘‘(i) provide technical assistance to the 
Board; and 
‘‘(ii) support the review process of the 
Board with respect to the agency under 
section 7906 in a non-voting staff capacity. 
‘‘(B) PROHIBITION.—A representative of 
an agency designated under subparagraph (A) 
and any employee of an agency may not directly 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00024
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
or indirectly influence in any capacity a deter-
mination by the Board under section 7906 with 
respect to life sciences research funded by the 
agency. 
‘‘(c) COMPENSATION.—Subject to such rules as may 
be adopted by the Board, without regard to the provisions 
of title 5 governing appointments in the competitive serv-
ice and without regard to the provisions of chapter 51 and 
subchapter III of chapter 53 of that title relating to classi-
fication and General Schedule pay rates, the Executive Di-
rector of the Board shall— 
‘‘(1) be compensated at a rate not to exceed the 
rate of basic pay for level II of the Executive Sched-
ule; 
‘‘(2) serve the entire tenure as Executive Direc-
tor as 1 full-time employee; and 
‘‘(3) appoint and fix the compensation of such 
other personnel as may be necessary to carry out 
this chapter. 
‘‘§ 7904. Board mission and functions 
‘‘(a) MISSION.—The mission of the Board shall be 
to issue an independent determination as to whether an 
agency may award Federal funding for proposed high-risk 
life sciences research, which shall be binding upon the 
agency. 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00025
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(b) POWERS.—The Board shall have the authority 
to act in a manner to carry out the mission described in 
subsection (a), including authority to— 
‘‘(1) prescribe regulations to carry out the re-
sponsibilities of the Board; 
‘‘(2) establish a process for the review of Fed-
eral funding for high-risk life sciences research prior 
to the award of the Federal funding, which shall be 
binding upon an agency, including information des-
ignated as classified or otherwise protected from dis-
closure; 
‘‘(3) direct an agency to make available to the 
Board additional information and records, including 
information designated as classified or otherwise 
protected from disclosure, that the Board determines 
are required to fulfill the functions and responsibil-
ities Board under this chapter; 
‘‘(4) review any classified research conducted or 
funded by any agency to determine whether the re-
search would be considered high-risk life sciences re-
search; and 
‘‘(5) through the promulgation of regulations, 
establish processes, policies, and procedures of the 
Board for rendering decisions under this chapter. 
‘‘(c) INITIAL REQUIREMENTS.—The Board shall— 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00026
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(1) not later than 180 days after the date of 
appointment of the initial members of the Board 
under section 7902, publish procedures in the Fed-
eral Register establishing the process for the review 
by the Board under section 7906; 
‘‘(2) prior to the establishment of the proce-
dures under paragraph (1), consult with the appro-
priate congressional committees and heads of agen-
cies for purposes of developing such procedures; and 
‘‘(3) not later than 270 days after the date of 
the enactment of this chapter, begin carrying out the 
duties described in section 7906. 
‘‘(d) RESPONSIVENESS
TO
CONGRESS.—Notwith-
standing any other provision of law, not later than 30 days 
after the date on which the Board receives a request for 
information from a Member of Congress, the Board shall 
respond to the request. 
‘‘(e) CONGRESSIONAL BRIEFINGS.—Not less fre-
quently than quarterly, the Board shall brief the appro-
priate congressional committees on the work of the Board. 
‘‘(f) SELECT AGENT OR TOXIN UPDATES.— 
‘‘(1) IN
GENERAL.—Not later than 15 days 
after the date on which the Board receives a notifi-
cation that a select agent or toxin has been added 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00027
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
to a list of agent or toxins under a regulation de-
scribed in paragraph (2), the Board shall— 
‘‘(A) review the select agent or toxin; 
‘‘(B) by majority vote of members of the 
Board, determine whether the select agent or 
toxin should be added into the definition of ‘se-
lect agent or toxin’ under section 7901; and 
‘‘(C) publish any addition determined 
under subparagraph (B) in the Federal Reg-
ister. 
‘‘(2) REGULATIONS DESCRIBED.—A regulation 
described in this paragraph is— 
‘‘(A) section 73.3(b) of title 42, Code of 
Federal Regulations, or any successor regula-
tion; 
‘‘(B) section 331.3(b) of title 7, Code of 
Federal Regulations, or any successor regula-
tion; and 
‘‘(C) section 121.3(b) of title 9, Code of 
Federal Regulations, or any successor regula-
tion. 
‘‘(g) FINAL DETERMINATION AUTHORITY.—In any 
dispute with an agency or entity relating to the classifica-
tion of life sciences research under this chapter, the Board 
shall retain final and ultimate authority in— 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00028
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(2) EFFECTIVE
DATE.—Paragraph (1) shall 
take effect on the date that is 180 days after the 
date of enactment of this chapter. 
‘‘(b) HIGH-RISK ATTESTATION; SELECT AGENT OR 
TOXIN DISCLOSURE; CERTIFICATION.— 
‘‘(1) IN GENERAL.—An entity seeking Federal 
funding from an agency for life sciences research 
shall, under the penalty of perjury— 
‘‘(A) attest whether— 
‘‘(i) the life sciences research will con-
stitute high-risk life sciences research; and 
‘‘(ii) the entity is performing active 
research with a select agent or toxin; and 
‘‘(B) if the entity makes a positive attesta-
tion under subparagraph (A), disclose the 
source of funding for all active research. 
‘‘(2) ACTIVE RESEARCH WITH SELECT AGENTS 
OR TOXINS.— 
‘‘(A) IN GENERAL.—The head of an agen-
cy that receives a disclosure from an entity 
under paragraph (1)(B) shall submit to the 
Board the disclosure. 
‘‘(B) BOARD INQUIRIES.—The Board may 
contact an entity that submits a disclosure 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00030
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
under paragraph (1)(B) to request additional 
information relating to the disclosure. 
‘‘(3) AGENCY CERTIFICATION.— 
‘‘(A) POSITIVE ATTESTATIONS.—The head 
of an agency making an award of Federal fund-
ing to an entity that makes a positive attesta-
tion under paragraph (1)(A)(i) shall— 
‘‘(i) submit to the Board the high-risk 
life sciences proposal; and 
‘‘(ii) using the process established by 
the head of the agency under paragraph 
(4), certify the validity of the attestation. 
‘‘(B) 
NEGATIVE
ATTESTATIONS.—The 
head of an agency making an award of Federal 
funding to an entity that makes a negative at-
testation under paragraph (1)(A)(i) shall— 
‘‘(i) review the attestation; and 
‘‘(ii) using the process established by 
the head of the agency under paragraph 
(4), certify the validity of the attestation. 
‘‘(4) PROCESS FOR REVIEW.—The head of each 
agency that awards Federal funding for life sciences 
research, in consultation with the Board, shall estab-
lish and implement a process for identifying pro-
posals from entities seeking Federal funding for life 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00031
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
sciences research from the agency that will con-
stitute high-risk life sciences research. 
‘‘(5) MAINTENANCE OF RECORDS.—The head of 
each agency shall— 
‘‘(A) maintain records of the certification 
process described in paragraph (3) for each ap-
plication for Federal funding in accordance with 
chapter 31 of title 44; and 
‘‘(B) make the records maintained under 
subparagraph (A) available for audit and review 
upon request by the Board. 
‘‘(c) NOTIFICATION.— 
‘‘(1) IN GENERAL.—Not later than 30 days be-
fore the date on which the head of an agency plans 
to award Federal funding to an entity for life 
sciences research, the head of the agency shall sub-
mit to the Board a notification of the proposed Fed-
eral funding. 
‘‘(2) CONTENTS.—The notification of Federal 
funding for life sciences research required under 
paragraph (1) shall include the attestation and cer-
tification required under subsection (b). 
‘‘(3) BOARD REQUESTS.— 
‘‘(A) IN GENERAL.—The Board may re-
quest additional information from the head of 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00032
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
an agency relating to a notification submitted 
under paragraph (1). 
‘‘(B) PROVISION
OF
INFORMATION.—The 
head of an agency from which the Board re-
quests additional information under subpara-
graph (A) shall provide the information in a 
timely manner. 
‘‘(d) AGENCY PROCEDURES.—Not later than 180 
days after the date on which the Board publishes the proc-
ess of the Board in the Federal Register pursuant to sec-
tion 7904(c), the head of each agency shall publish on the 
website of the agency prepayment and preaward proce-
dures of the agency with respect to Federal funding for 
life sciences research to— 
‘‘(1) guarantee that— 
‘‘(A) all high-risk life science research pro-
posals are referred to the Board before the 
award of Federal funding by the agency; 
‘‘(B) no Federal funding for high-risk life 
sciences research is awarded by the agency 
without approval by the Board; and 
‘‘(C) not later than 30 days before the 
date on which the head of the agency plans to 
award the Federal funding, the agency notifies 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00033
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
the Board of the proposal for Federal funding; 
and 
‘‘(2) otherwise ensure compliance with this 
chapter. 
‘‘(e) PROVISION OF ADDITIONAL INFORMATION.— 
Upon request by the Board, the head of an agency shall 
provide any information relating to Federal funding 
awards for life sciences research determined necessary by 
the Board to provide oversight of the agency. 
‘‘(f) CHANGE
IN
CIRCUMSTANCES
DURING
RE-
SEARCH.—If, during the course of life sciences research 
in progress performed by an entity supported by Federal 
funding from an agency, circumstances arise such that the 
life sciences research in progress may constitute high-risk 
life sciences research in contravention to the attestation 
of the entity under subsection (b)(1)(A)(i)— 
‘‘(1) the entity shall— 
‘‘(A) not later than 24 hours after the 
identification of the change in circumstance, 
pause the life sciences research in progress; and 
‘‘(B) not later than 5 days after the date 
of the identification of the change in cir-
cumstance, submit to the head of the agency a 
written notification through an electronic or 
nonelectronic communication method that— 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00034
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(i) notifies the head of the agency of 
the possibility that the life sciences re-
search in progress may constitute high-risk 
life sciences research; and 
‘‘(ii) includes a detailed description of 
each change in circumstance that may 
transform the life sciences research in 
progress into high-risk life sciences re-
search; and 
‘‘(2) the head of the agency shall— 
‘‘(A) using the process of the agency estab-
lished 
under 
subsection 
(b)(4), 
determine 
whether the life sciences research in progress 
constitutes high-risk life sciences research; 
‘‘(B) if the head of the agency makes a 
negative determination under subparagraph 
(A), inform the entity that the entity may re-
sume the life sciences research in progress; and 
‘‘(C) if the head of the agency makes a 
positive determination under subparagraph (A), 
immediately submit to the Board a notification 
of the Federal funding of high-risk life sciences 
research in progress for review under section 
7906(a)(1). 
‘‘(g) ENFORCEMENT.— 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00035
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(1) APPLICANT REQUIREMENTS.—If an entity 
seeking or receiving Federal funding from an agency 
knowingly fails to make a true attestation under 
subsection (b)(1) or promptly notify the agency of a 
change in circumstance in accordance with sub-
section (f)(1), the head of the agency shall refer the 
entity to the appropriate entity for suspension and 
debarment proceedings relating to the receipt of 
Federal funding. 
‘‘(2) REFERRAL TO INSPECTOR GENERAL.—The 
Board shall refer any employee of an agency respon-
sible for overseeing and reviewing research proposals 
relating to Federal funding that knowingly fails to 
comply with subsection (b)(3) to the inspector gen-
eral of the agency. 
‘‘(3) EMPLOYEE DISCIPLINE.— 
‘‘(A) IN GENERAL.—The head of an agen-
cy employing an employee who knowingly vio-
lates any provision of subsection (b)(3) (or, in 
the case of the head of an agency who violates 
any provision of subsection (b)(3), the Presi-
dent) shall impose on that employee— 
‘‘(i) disciplinary action in accordance 
with chapter 75 of title 5 or an equivalent 
procedure of the agency; and 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00036
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(ii) permanent revocation of any ap-
plicable security clearance held by the em-
ployee. 
‘‘(B) CONTRACTOR PENALTY.—In the case 
of contractor working under a contract with an 
agency who knowingly violates subsection 
(b)(1), the head of the agency shall refer the 
contractor to the appropriate entity for suspen-
sion and debarment proceedings relating to the 
receipt of Federal funding. 
‘‘(C) EMPLOYEE DISCIPLINE REPORTS.— 
‘‘(i) IN
GENERAL.—Not later than 
360 days after the date of enactment of 
this Act, and not less frequently than once 
every 90 days thereafter, the head of each 
agency shall submit to the Board and the 
appropriate congressional committees a re-
port that discloses, for the period covered 
by the report, each violation by an em-
ployee of the agency of subsection (b)(3). 
‘‘(ii) CONTENTS.—Each report sub-
mitted under clause (i) shall include, with 
respect to a violation described in that 
clause— 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00037
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(I) the name and professional 
title of each employee engaged in the 
violation; 
‘‘(II) a detailed explanation of 
the nature of the violation; and 
‘‘(III) the date of the violation. 
‘‘(iii) PUBLICATION.—Not later than 
5 days after the date on which the Board 
receives a report under clause (i), the 
Board shall publish on a publicly accessible 
and searchable website the amount of vio-
lations that have been committed under 
clause (i). 
‘‘(h) SUBAWARD
AND
SUBCONTRACTOR
DISCLO-
SURE.— 
‘‘(1) IN GENERAL.—During the course of high- 
risk life sciences research in progress performed by 
an entity supported by Federal funding from an 
agency, the entity shall— 
‘‘(A) continuously disclose to the head of 
the agency any subcontracts or subawards made 
or planned to be made with the Federal fund-
ing; and 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00038
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(B) obtain consent from the head of the 
agency before awarding a subcontract or award 
described in subparagraph (A). 
‘‘(2) AGENCY SUBMISSION.—Not later than 30 
days after the date on which the head of an agency 
receives a disclosure under paragraph (1), the head 
of the agency shall submit to the Board the disclo-
sure. 
‘‘(3) BOARD INQUIRIES.— 
‘‘(A) IN GENERAL.—The Board may con-
tact an entity that submits a disclosure under 
paragraph (1) to request additional information 
relating to the disclosure. 
‘‘(B) ACCESS
TO
REPORTS.—During the 
course of high-risk life sciences research in 
progress performed by an entity supported by 
Federal funding from an agency, upon request, 
the Board shall have access to every annual re-
port of— 
‘‘(i) the agency; 
‘‘(ii) the entity performing the high- 
risk life sciences research; and 
‘‘(iii) 
any 
subcontractor 
or 
sub-
awardee of an entity described in clause 
(ii). 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00039
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘§ 7906. Board review 
‘‘(a) IN GENERAL.— 
‘‘(1) HIGH-RISK LIFE SCIENCES RESEARCH.— 
Not later than 120 days after the date on which the 
Board receives a notification from an agency under 
section 7905(c) relating to proposed Federal funding 
for life sciences research that constitutes high-risk 
life sciences research or the Board receives a notifi-
cation from an agency under section 7905(f)(2)(C) 
relating to Federal funding of research in progress 
that constitutes high-risk life sciences research, the 
Board shall— 
‘‘(A) review the proposed Federal funding 
or high-risk life sciences research in progress; 
‘‘(B) by a majority vote, determine wheth-
er the agency may award the proposed Federal 
funding or continue to award the Federal fund-
ing for the high-risk life sciences research in 
progress; and 
‘‘(C) by a majority vote, determine with re-
spect to the high-risk life sciences research 
funded by the proposed Federal funding or 
Federal funding for high-risk life sciences re-
search in progress— 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00040
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(i) the minimum required biosafety 
containment level, engineering controls, 
and operational controls; 
‘‘(ii) the minimum required biosecu-
rity engineering controls and operational 
controls; and 
‘‘(iii) the minimum required personnel 
assurance controls. 
‘‘(2) PROPOSED LIFE SCIENCES RESEARCH.— 
‘‘(A) IN GENERAL.—With respect to pro-
posed Federal funding by an agency for life 
sciences research, the Board may— 
‘‘(i) review the proposed Federal fund-
ing; and 
‘‘(ii) determine whether the Board 
should review the proposed Federal fund-
ing in accordance with paragraph (1). 
‘‘(B) NOTIFICATION.—If the Board makes 
a positive determination under subparagraph 
(A)(ii) with respect to proposed Federal funding 
by an agency— 
‘‘(i) the Board shall notify the head of 
the agency; and 
‘‘(ii) the head of the agency may not 
award the proposed Federal funding until 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00041
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
the date on which the Board makes a final 
determination with respect to the proposed 
Federal funding under paragraph (1). 
‘‘(3) PAST
FUNDING.—With respect to life 
sciences research performed with Federal funding 
awarded by an agency before the date of enactment 
of this chapter, the Board may review and audit the 
research in order to assess the compliance of the 
agency with the provisions of this chapter. 
‘‘(4) ONGOING FUNDING FOR LIFE SCIENCES 
RESEARCH.—With respect to Federal funding for 
life sciences research in progress awarded by an 
agency before the date of enactment of this Act that 
the Board determines may constitute high-risk life 
sciences research, the Board may— 
‘‘(A) direct the agency to temporarily sus-
pend the Federal funding; 
‘‘(B) require the agency to provide com-
plete information on the Federal funding in 
order for the Board to complete a review of the 
life sciences research under paragraph (1); and 
‘‘(C) by a majority vote of members of the 
Board, determine whether the agency may con-
tinue the Federal funding. 
‘‘(b) CONSIDERATIONS.— 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00042
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(1) IN GENERAL.—In making a determination 
under subsection (a)(1)(B), the Board shall con-
sider, with respect to the high-risk life sciences re-
search that will be conducted with the proposed Fed-
eral funding or high-risk life sciences research in 
progress— 
‘‘(A) whether the research poses a threat 
to public health; 
‘‘(B) whether the research poses a threat 
to public safety; 
‘‘(C) whether the research has a high prob-
ability of producing benefits for public health; 
‘‘(D) whether the research poses a threat 
to large populations of animals and plants; 
‘‘(E) whether the research poses a threat 
to national security; 
‘‘(F) whether the research is proposed to 
be conducted in whole or at least in part in a 
foreign country; 
‘‘(G) the reasonably anticipated material 
risks of the research; 
‘‘(H) the reasonably anticipated informa-
tion risks of the research; 
‘‘(I) the reasonably anticipated benefits of 
the research; 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00043
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(B) BOARD RESPONSE.—The Board shall 
schedule a meeting requested by the head of an 
agency under subparagraph (A) in a timely 
manner. 
‘‘(3) NOTIFICATION TO APPROPRIATE CONGRES-
SIONAL COMMITTEES.—If the Board determines that 
the head of an agency may not proceed with an 
award of proposed Federal funding under this sec-
tion, the Executive Director of the Board shall no-
tify the appropriate congressional committees when 
the Board notifies the head of the agency. 
‘‘(d) REQUEST FOR EXPEDITED REVIEW.— 
‘‘(1) DEFINITION.—In this subsection, the term 
‘emergency research’ means high-risk life sciences 
research submitted to the Board that relates to a 
public health emergency or addresses a specific na-
tional security concern. 
‘‘(2) REQUEST; NOTIFICATION.—The head of 
an agency seeking expedited review from the Board 
to award Federal funding for emergency research 
shall— 
‘‘(A) include a request for expedited review 
in the notification required under section 
7905(c); and 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00045
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(B) on the date of the notification de-
scribed in subparagraph (A), submit to the 
Board and the appropriate congressional com-
mittees a notification that explains why the spe-
cific public health emergency or national secu-
rity concern necessitates expedited review under 
this subsection. 
‘‘(3) INTERNAL PROCESS.—The Board shall es-
tablish an internal process under which the Board 
will give proposed emergency research expedited re-
view under this section. 
‘‘(4) TEMPORARY EMERGENCY RESEARCH.—If 
the Board does not notify the head of an agency 
with a determination under subsection (a)(1)(B) 
with respect to proposed emergency research by the 
date that is 15 days after the date on which the 
head of the agency submits a request under para-
graph (2)(A), the head of the agency may award 
Federal funding for the emergency research on a 
temporary basis. 
‘‘(e) SCIENTIFIC EXPERT PANELS.— 
‘‘(1) IN GENERAL.—The Board may establish a 
scientific panel of nongovernmental experts to advise 
the Board in the review by the Board of life sciences 
research pursuant to this chapter. 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00046
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(2) POLICIES AND PROCEDURES.—The Board 
shall establish and publish in the Federal Register 
procedures and policies relating to conflicts of inter-
est, recusal, expertise, and related matters before 
the establishment of the panel described in para-
graph (1). 
‘‘(3) PROHIBITION.—An individual serving on 
the panel established under paragraph (1) may not 
advise the Board on any matter with respect to 
which the individuals has an identified or perceived 
conflict of interest. 
‘‘(4) REPORT.— 
‘‘(A) IN
GENERAL.—Not later than 30 
days after the date on which the Board estab-
lishes a panel established under paragraph (1), 
the Board shall submit to the appropriate con-
gressional committees a report that includes the 
names, qualifications, and any identified or per-
ceived conflicts of interest of individuals who 
serve on the panel. 
‘‘(B) PANEL CHANGES.—Upon a change of 
personnel on the panel established under para-
graph (1), the Board shall immediately submit 
to the appropriate congressional committees an 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00047
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
update to the report required under subpara-
graph (A). 
‘‘(f) REPORT.— 
‘‘(1) IN GENERAL.—Not later than 360 days 
after the date on which the Board establishes the 
panel described in subsection (e)(1), and annually 
thereafter, the Board shall submit to the appropriate 
congressional committees a report, which shall in-
clude a classified annex, summarizing, with respect 
to each determination by the Board under this sec-
tion relating to high-risk life sciences research— 
‘‘(A) the findings of the Board; 
‘‘(B) the determination of the Board; 
‘‘(C) the name and location of the entity 
proposing the life sciences research; 
‘‘(D) the name and location of any recipi-
ent of a subaward or subcontractor of an entity 
proposing life sciences research and the nature 
of the participation of such a recipient or sub-
contractor; and 
‘‘(E) an account of significant challenges 
or problems, including procedural or substantive 
challenges or problems, that arise during the 
course of the work of the Board, including the 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00048
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS
views of any member of the Board who wishes 
to have those views included in the report. 
‘‘(2) PUBLIC REPORT.—On the date on which 
the Board submits a report required under para-
graph (1), the Board shall make the report, other 
than the classified annex included in the report, 
available on a website. 
‘‘(g) EFFECTIVE DATE.—This section shall take ef-
fect on the date that is 270 days after the date of enact-
ment of this chapter. 
‘‘§ 7907. GAO Audits 
‘‘The Comptroller General of the United States shall 
periodically audit the Board. 
‘‘§ 7908. Funding 
‘‘There is authorized to be appropriated to the Board 
to carry out this chapter $30,000,000 for each of fiscal 
years 2026 through 2035.’’. 
(b) CLERICAL AMENDMENT.—The table of chapters 
for subtitle V of title 31, United States Code, is amended 
by adding at the end the following: 
‘‘79. Life Sciences Research Security Board .......................................... 7901’’. 
(c) FINANCIAL DISCLOSURE REPORTS
OF BOARD 
MEMBERS.—Section 13103(f) of title 5, United States 
Code, is amended— 
(1) in paragraph (11), by striking ‘‘and’’ at the 
end; 
VerDate Sep 11 2014 
19:37 Mar 22, 2025
Jkt 059200
PO 00000
Frm 00049
Fmt 6652
Sfmt 6201
E:\BILLS\H1864.IH
H1864
ssavage on LAPJG3WLY3PROD with BILLS